Multiple sclerosis
For patient information click here
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Synonyms and keywords: Disseminated sclerosis; encephalomyelitis disseminata; Ms; Demyelinating Autoimmune Disease; multipel sclerosis; multiple scelerosis; multipel scelerosis
Overview
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
Multiple sclerosis is a disease of the central nervous system and it’s known to be multi factorial. The most common risk factors in the development of multiple sclerosis are smoking, genetic, ethnic, infection, low vitamin D, and stress. Whatever the trigger is, it will lead to an acquired immune response followed by inflammatory reactions. These reactions lead to secretion of cytokines in the CNS parenchyma and activation of resident microglia. Microglia cells activate astrocytes to release more inflammatory cytokines, leading to recruitment and infiltration of circulatory leukocytes. This burst events cause destruction of myelin sheath and forms focal sclerotic white matter plaques, which are characteristic of multiple sclerotic disease. The onset of symptoms is mostly between the age of fifteen to forty years, rarely before age fifteen or after age sixty and include fatigue, mood problems, spasticity, bowel and bladder dysfunction, cognitive impairment, eye movement problems, heat sensitivity, incoordination, pain, sexual dysfunction, sleep disorder, vertigo and visual loss. There is no single diagnostic study of choice for the diagnosis of multiple sclerosis, but multiple sclerosis can be diagnosed based on clinical presentation, cerebral plaques on MRI , and oligoclonal bands in CSF analysis. The predominant therapy for multiple sclerosis is disease-modifying treatment in relapsing-remitting multiple sclerosis, immunosuppressive threpay in progressive multiple sclerosis and Glucocorticoid therapy in acute exacerbation.
Historical Perspective
Multiple sclerosis was first described by a neurologist, Dr. Jean Martin Charcot in 1868 and named sclerose en plaque. The signs and symptoms including dysarthria, ataxia and tremor were called charcot’s triad.
Classification
Multiple sclerosis may be classified into four groups according to clinical course of the disease including relapsing-remitting, secondary-progressive, primary-progressive and progressive-relapsing. other variants of Multiple sclerosis include clinically isolated syndrome and radiologically isolated syndrome.
Pathophysiology
Multiple sclerosis is a disease of the central nervous system and it’s known to be multi factorial. Whatever the trigger is, it will lead to an acquired immune response followed by inflammatory reactions. These reactions lead to secretion of cytokines in the CNS parenchyma and activation of resident microglia. Microglia cells activate astrocytes to release more inflammatory cytokines, leading to recruitment and infiltration of circulatory leukocytes. This burst events cause destruction of myelin sheath and forms focal sclerotic white matter plaques, which are characteristic of multiple sclerotic disease. There is some evidence proving genetic involvement in onset of MS so that it increases the risk of developing MS from 0.1% in general population to 3% in those who have siblings with MS and 25% in those with a mono-zygote twin affected. Based on studies performed on post mortem brain tissue of patients with multiple sclerosis, there are four types of white matter lesion pathology. Damage to myelin sheath is prominent in type 1 and 2 while type 3 and 4 characteristic is dying oligodendrocytes. the etiology of oligodendrocytes death known to be multi-factorial or followed by hypoxia, mitochondrial dysfunction and macrophages.
Causes
Multiple sclerosis may be caused by different categories of causes include: Autoimmunity, genetic, infectious and degeneration.
Differentiating Multiple Sclerosis from other Diseases
Multiple sclerosis must be differentiated from other diseases that can mimic this disease clinically or radiologically such as systemic lupus erythematosis, Sjögren’s syndrome, vasculitis, neuro-behçet’s disease, sarcoidosis, antiphospholipid (Hughes) syndrome , susac syndrome, lyme disease, syphilis, HTLV-1 infection, HIV-Related Disorders of the CNS, migraine, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, leber’s hereditary optic neuropathy, vitamin B12 deficiency, metachromatic leukodystrophy, Fabry’s disease, Krabbe’s disease, adrenoleukodystrophy, mitochondrial encephalopathy epilepsy lactic acidosis and stroke like episode, stroke, primary CNS lymphoma , and dural arteriovenous fistula and true malformations.
Epidemiology and Demographics
The majority of multiple sclerosis cases are reported in northern Europe, continental North America, and Australasia, which is about one of every 1000 citizens. Factors including sunlight exposure, climate, diet, toxins, genetic factors, geomagnetism, Childhood environmental factors and infections have been proved to cause these differences in MS prevalence. MS is at least two times more common among women than men. The onset of symptoms is mostly between the age of fifteen to forty years, rarely before age fifteen or after age sixty.
Risk Factors
Common risk factors in the development of multiple sclerosis are smoking, genetic, ethnic, infection, low vitamin D, and stress. Less common risk factors in the development of multiple sclerosis include African Americans, Mexicans, Japanese, Chinese and Filipinos race and Epstein-Barr virus.
Natural History, Complications and Prognosis
Multiple sclerosis usually start between age of fifteen to forty years, rarely before age fifteen or after age sixty with symptoms such as optic neuritis, diplopia, sensory or motor loss, vertigo and balance problems. It may be classified into four groups according to clinical course of the disease including relapsing-remitting, secondary-progressive, primary-progressive, and progressive-relapsing. Complications that can develop as a result of multiple sclerosis are: medication complication, Fatigue, mood problems, Spasticity, Bowel and bladder dysfunction, Cognitive impairment, Heat sensitivity., Incoordination, Pain, Sexual dysfunction, Sleep disorders, vertigo, visual loss. there are some factors associated with a particularly poor prognosis among patients with multiple sclerosis such as: Relapsing versus progressive disease, early symptoms, Demographics, Sex, Smoking.
Diagnosis
Diagnostic Study of choice
There is no single diagnostic study of choice for the diagnosis of multiple sclerosis, but multiple sclerosis can be diagnosed based on clinical presentation, MRI findings, and CSF analysis. Sequence of diagnostic studies are history and physical examination, imaging, and CSF analysis. The findings are cerebral plaques which are demyelinating areas on MRI and an elevated concentration of CSF oligoclonal bands. The diagnostic criteria for multiple sclerosis is McDonald criteria.
History and Symptoms
The most common symptoms of multiple sclerosis include: Fatigue, mood problems, spasticity, bowel and bladder dysfunction, cognitive impairment, eye movement problems, heat sensitivity, incoordination, pain, sexual dysfunction, sleep disorder, vertigo and visual loss.
Physical Examination
Physical examination of patients with multiple sclerosis is usually remarkable for lhermitte’s sign, spasticity, increased reflexes, internuclear ophthalmoplegia, optic neuritis, gait disturbance, and urinary incontinence.
Laboratory Findings
An elevated concentration of CSF oligoclonal bands is diagnostic of multiple sclerosis.
Electrocardiogram
An ECG may be helpful in the diagnosis of multiple sclerosis. Findings on an ECG suggestive of multiple sclerosis include atrial fibrillation, ventricular arrhythmia, shortened or longed P-R interval, tall waves or peaked waves, U waves, and Q waves.
X-ray
There are no x-ray findings associated with multiple sclerosis.
Echocardiography and Ultrasound
There are no echocardiography/ultrasound findings associated with multiple sclerosis.
CT scan
Findings on CT scan suggestive of multiple sclerosis include brain atrophy and some contrast enhancing plaques. Findings on an Double delayed high dose CT scan suggestive of Multiple sclerosis include enhanced lesions in double delayed high dose CT scan which are indicators of blood brain barrier disruption.
MRI
On MRI, multiple sclerosis is characterized by cerebral plaques disseminating in space and time which are characteristic of demyelinating areas. These lesions are commonly void, and located in periventricular white matter, cerebellum, and the brain stem. These lesions are hyperintense on T2 sections of a MRI.
Other Imaging Findings
There is no other imaging findings associated with multiple sclerosis.
Other Diagnostic Studies
Visual evoked potential studies, antimyelin antibodies, and optimal coherence tomography may be helpful in the diagnosis of multiple sclerosis.
Treatment
Medical Therapy
The predominant therapy for multiple sclerosis is disease-modifying treatment in relapsing-remitting multiple sclerosis, immunosuppressive threpay in progressive multiple sclerosis and Glucocorticoid therapy in acute exacerbation.
Surgery
Surgery can be helpful in controlling trigeminal neuralgia, tremor, and ataxia.
Alternative Therapies
Alternative treatments for multiple sclerosis are: Dietary regimens herbal medicine ( marijuana ) hyperbaric oxygenation therapeutic practice of martial arts.
Primary Prevention
Effective measures for the primary prevention of multiple sclerosis include: Vitamin D supplement, smoking cessation, early exposure to infections.
Secondary Prevention
There is no established method for secondary prevention of multiple sclerosis.
Tertiary Prevention
Tertiary: There is strong evidence that exercise therapy can improve muscle function and mobility in multiple sclerosis patients.
References
Historical Perspective
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.,
Overview
Multiple sclerosis was first described by a neurologist, Dr. Jean Martin Charcot in 1868 and named sclerose en plaque. The signs and symptoms including dysarthria, ataxia, and tremor were called ‘Charcot’s triad‘.
Historical Perspective
Discovery
- Multiple sclerosis was first described by a neurologist, Dr. Jean martin Charcot in 1868.
- Previously, Dr. Robert Hooper (1773-1835), Robert Carswell (1793-1857), and Jean Cruveilhier (1791-1873) had noticed some of the MS clinical manifestations, but for the first time, Dr. Charcot described it as a distinct disease and named sclerose en plaque.
- The signs and symptoms including dysarthria, ataxia, and tremor, were called charcot’s triad by Dr. Charcot for the first time.
Famous Cases
- One of the first suspected MS patients in history is Saint Lidwina (1380-1433). She had symptoms such as pain, lower extremities weakness, and vision loss.[1][2]
- The other MS suspected patient in history is Augustus Frederick d’este (1794-1848). His symptoms began at the age of 28 with vision loss, bladder dysfunction, numbness, weakness of legs and sexual dysfunction.[3]
References
- ↑ Charcot, J. Histologie de la sclerose en plaques. Gazette des hopitaux, Paris, 1868; 41: 554–555.
- ↑ Poser C (1994). “The dissemination of multiple sclerosis: a Viking saga? A historical essay”. Ann. Neurol. 36 Suppl 2: S231–43. PMID 7998792.
- ↑ Firth, D (1948). The Case of August D`Esté. Cambridge: Cambridge University Press.
Classification
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
Multiple sclerosis may be classified into four groups according to the clinical course of the disease. This includes relapsing-remitting, secondary-progressive, primary-progressive, and progressive-relapsing.
Classification
- Multiple sclerosis may be classified according to its clinical course into four groups:[1][2]
- In 1996, US National Multiple Sclerosis Society (NMSS) defined multiple sclerosis subtypes according to clinical manifestations.
- The fact that the clinical course of the disease is a dynamic process makes it possible that the subtypes switch to each other over time.
| Subtypes | Explanation |
|---|---|
| Relapsing remitting |
|
| Secondary progressive |
|
| Primary progressive |
|
| Progressive relapsing |
|
Other new multiple sclerosis subclasses
- In recent studies a new subtype of multiple sclerosis was defined as “clinically isolated syndrome (CIS).” It is when the clinical presentation of a disease is suggestive of myelin sheath inflammation but cannot fulfill the diagnostic criteria of MS.[2][3]
- Another associated termination regarding MS classification is “radiologically isolated syndrome (RIS).” It defines as radiological findings of myelin sheath inflammation without any sign or symptoms in patient. RIS can be an indicator of early stages of MS disease, but it’s not a subgroup of MS because radiological finding of inflammatory demyelination without any sign or symptoms of the disease is nonspecific.[2]
References
- ↑ Lublin FD; Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996 Apr;46(4):907-11. PMID 8780061
- ↑ 2.0 2.1 2.2 Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, Thompson AJ, Wolinsky JS, Balcer LJ, Banwell B, Barkhof F, Bebo B, Calabresi PA, Clanet M, Comi G, Fox RJ, Freedman MS, Goodman AD, Inglese M, Kappos L, Kieseier BC, Lincoln JA, Lubetzki C, Miller AE, Montalban X, O’Connor PW, Petkau J, Pozzilli C, Rudick RA, Sormani MP, Stüve O, Waubant E, Polman CH (2014). “Defining the clinical course of multiple sclerosis: the 2013 revisions”. Neurology. 83 (3): 278–86. doi:10.1212/WNL.0000000000000560. PMC 4117366. PMID 24871874.
- ↑ Katz Sand I (2015). “Classification, diagnosis, and differential diagnosis of multiple sclerosis”. Curr. Opin. Neurol. 28 (3): 193–205. doi:10.1097/WCO.0000000000000206. PMID 25887774.
Pathophysiology
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.,
Overview
Multiple sclerosis is a disease of the central nervous system and it’s known to be multi factorial. Whatever the trigger is, it will lead to an acquired immune response followed by inflammatory reactions. These reactions lead to secretion of cytokines in the CNS parenchyma and activation of resident microglia. Microglia cells activate astrocytes to release more inflammatory cytokines, leading to recruitment and infiltration of circulatory leukocytes. This burst events cause destruction of myelin sheath and forms focal sclerotic white matter plaques, which are characteristic of multiple sclerotic disease. There is some evidence proving genetic involvement in onset of MS so that it increases the risk of developing MS from 0.1% in general population to 3% in those who have siblings with MS and 25% in those with a monozygote twin affected. Based on studies performed on post mortem brain tissue of patients with multiple sclerosis, there are four types of white matter lesion pathology. Damage to myelin sheath is prominent in type 1 and 2 while type 3 and 4 characteristic is dying oligodendrocytes. the etiology of oligodendrocytes death known to be multifactorial or followed by hypoxia, mitochondrial dysfunction and macrophages.
Pathophysiology
Physiology
- Soma is the neuronal cell body which is a closed area with cell membrane.[1]
- Myelin sheath is the oligodendrocyte membrane which wraps around the axons.
- Myelin sheath is insulated against electrical impulses and is separated by nodes of Ranvier which can transfer the electrical impulse.
- This structure leads to fast traveling of electrical impulses.
Pathogenesis
- Multiple sclerosis is a disease of the central nervous system and it’s known to be multi factorial.[2]
- There are both inflammation and degeneration in the course of the disease, but as it progress, degeneration becomes more prominent.
- There are variety of different cells participating in MS pathophysiology. Whatever the trigger is, it will lead to an acquired immune response followed by inflammatory reactions.
- These reactions lead to secretion of cytokines in CNS parenchyma and activation of resident microglia. Microglia cells activate astrocytes to release more inflammatory cytokines leading to recruitment and infiltration of circulatory leukocytes.[3][4][5]
- This burst events cause destruction of myelin sheath and CNS tissue and releasing more auto antigens including myelin oligodendrocyte glycoprotein (MOG), myelin basic protein (MBP), proteolipid protein (PLP).[6][7]
- Focal sclerotic white matter plaques, which are characteristic of multiple sclerotic disease, are mostly located in the optic nerve, periventricular white matter, juxtacortical border, cerebellum, brain stem, and cervical spine.[8] This pattern of lesion formation is specific for MS.[9]
- Appearing of new white matter lesions is a way to estimate the efficacy of our therapy since it is an indicator of continued inflammation.[10]
- In the acute phase of the disease there is several evidence of blood brain barrier disruption.[11]
- Formation of white matter lesions is started by CD8+ T cells and then, CD4+ T cells, B cells, plasma cells and macrophages but the most common cells in lesions are macrophages and microglial cells.[12][13][14]
- There is some evidence of cortical (gray matter) demyelination in MS patients.[15][16] It correlates with cognitive deficits and seizures in patients.[17][18] It is not clear yet that whether the pathphysiology of cortical demyelination is similar to white matter demyelination and is a consequence of it or it is a completely different phenomenon.
- Cortical demyelination tends to be global in contrast with focal white matter lesions.[19]
- In post mortem brain tissue of patients with MS, gray matter lesions show blood brain barrier dysfunction, macrophages filled with myelin, T cells, B cells and meningeal inflammation. These findings are suggestive of inflammation as an underlying cause of these lesions.[20]
- Cortical demyelination is more prominent in PPMS and SPMS but it can also be seen in RRMS.[15]
- There are some lesions called “shadow plaques”. Remyelination occurs in these lesions and they have a large number of oligodendrocyte precursor cells (OPC) and mature oligodendrocytes.[21][22]
- It may be because of more permissive environment that this event occurs mostly in cortical lesions rather than white matter lesions.[21]
- Remyelination occurs equally among patients with RRMS, SPMS and PPMS.[23]
- The loss of mature oligodendrocytes in chronic MS is a sign of failure in the course of maturation.
- Several inhibitory mediators have been found to have a role in this and prevent the axonal attachment and expressing myelin-specific genes.[24][25]
- There are no imaging techniques which can differentiate remyelinated plaques from early demyelinating lesions. It seems that remyelinated plaques are more susceptible to demyelination attacks.
Genetics
- There is some evidence proving genetic involvement in onset of MS so that it increases the risk of developing MS from 0.1% in general population to 3% in those who have siblings with MS and 25% in those with a monozygote twin affected.[26]
- HLA alleles seems to have a huge relationship with MS susceptibility.[27]
Microscopic Pathology
Based on studies performed on post mortem brain tissue of patients with multiple sclerosis, there are four types of white matter lesion pathology:[28][8]
- Microscopic pathology type 1: Found in 10% of patients especially those with less than 1 year of disease history. In this type, the lesions have sharp borders and perivascular T cell infiltration. Demyelination process is still active and microglia cells and macrophages are full of myelin.
- Microscopic pathology type 2: Found in 55% of patients. IgG and complement (C9neo) deposition with sever macrophage and T cell infiltration.
- Microscopic pathology type 3: Found in 30% of patients. The borders of lesion in this type are not sharply defined. There are evidences of vessel inflammation and dying oligodendrocytes.
- Microscopic pathology type 4: Found in 5% of patients with PPMS. Degeneration of oligodendrocytes and infiltration of T cells and macrophages are seen in this type of lesions.[29]
NOTE: Damage to myelin sheath is prominent in type 1 and 2 while type 3 and 4 characteristic is dying oligodendrocytes.[8][30] the etiology of oligodendrocytes death known to be multifactorial or followed by hypoxia, mitochondrial dysfunction and macrophages.[31][32]


References
- ↑ Mattle, Heinrich (2017). Fundamentals of neurology : an illustrated guide. Stuttgart New York: Thieme. ISBN 9783131364524.
- ↑ Fiorini A, Koudriavtseva T, Bucaj E, Coccia R, Foppoli C, Giorgi A, Schininà ME, Di Domenico F, De Marco F, Perluigi M (2013). “Involvement of oxidative stress in occurrence of relapses in multiple sclerosis: the spectrum of oxidatively modified serum proteins detected by proteomics and redox proteomics analysis”. PLoS ONE. 8 (6): e65184. doi:10.1371/journal.pone.0065184. PMC 3676399. PMID 23762311.
- ↑ John GR, Lee SC, Song X, Rivieccio M, Brosnan CF (2005). “IL-1-regulated responses in astrocytes: relevance to injury and recovery”. Glia. 49 (2): 161–76. doi:10.1002/glia.20109. PMID 15472994.
- ↑ Kawakami N, Nägerl UV, Odoardi F, Bonhoeffer T, Wekerle H, Flügel A (2005). “Live imaging of effector cell trafficking and autoantigen recognition within the unfolding autoimmune encephalomyelitis lesion”. J. Exp. Med. 201 (11): 1805–14. doi:10.1084/jem.20050011. PMC 2213265. PMID 15939794.
- ↑ Sofroniew MV (2015). “Astrocyte barriers to neurotoxic inflammation”. Nat. Rev. Neurosci. 16 (5): 249–63. doi:10.1038/nrn3898. PMC 5253239. PMID 25891508.
- ↑ McCarthy DP, Richards MH, Miller SD (2012). “Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler’s virus-induced demyelinating disease”. Methods Mol. Biol. 900: 381–401. doi:10.1007/978-1-60761-720-4_19. PMC 3583382. PMID 22933080.
- ↑ Pirko I, Johnson AJ (2008). “Neuroimaging of demyelination and remyelination models”. Curr. Top. Microbiol. Immunol. 318: 241–66. PMID 18219821.
- ↑ 8.0 8.1 8.2 Mallucci G, Peruzzotti-Jametti L, Bernstock JD, Pluchino S (2015). “The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis”. Prog. Neurobiol. 127-128: 1–22. doi:10.1016/j.pneurobio.2015.02.003. PMC 4578232. PMID 25802011.
- ↑ Katz Sand I (2015). “Classification, diagnosis, and differential diagnosis of multiple sclerosis”. Curr. Opin. Neurol. 28 (3): 193–205. doi:10.1097/WCO.0000000000000206. PMID 25887774.
- ↑ Invalid
<ref>tag; no text was provided for refs namedpmid25665031 - ↑ Silver NC, Tofts PS, Symms MR, Barker GJ, Thompson AJ, Miller DH (2001). “Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study”. Mult. Scler. 7 (2): 75–82. doi:10.1177/135245850100700201. PMID 11424635.
- ↑ van Horssen J, Singh S, van der Pol S, Kipp M, Lim JL, Peferoen L, Gerritsen W, Kooi EJ, Witte ME, Geurts JJ, de Vries HE, Peferoen-Baert R, van den Elsen PJ, van der Valk P, Amor S (2012). “Clusters of activated microglia in normal-appearing white matter show signs of innate immune activation”. J Neuroinflammation. 9: 156. doi:10.1186/1742-2094-9-156. PMC 3411485. PMID 22747960.
- ↑ Johnson AJ, Suidan GL, McDole J, Pirko I (2007). “The CD8 T cell in multiple sclerosis: suppressor cell or mediator of neuropathology?”. Int. Rev. Neurobiol. 79: 73–97. doi:10.1016/S0074-7742(07)79004-9. PMID 17531838.
- ↑ Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH (2008). “B-cell depletion with rituximab in relapsing-remitting multiple sclerosis”. N. Engl. J. Med. 358 (7): 676–88. doi:10.1056/NEJMoa0706383. PMID 18272891.
- ↑ 15.0 15.1 Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H (2005). “Cortical demyelination and diffuse white matter injury in multiple sclerosis”. Brain. 128 (Pt 11): 2705–12. doi:10.1093/brain/awh641. PMID 16230320.
- ↑ De Stefano N, Matthews PM, Filippi M, Agosta F, De Luca M, Bartolozzi ML, Guidi L, Ghezzi A, Montanari E, Cifelli A, Federico A, Smith SM (2003). “Evidence of early cortical atrophy in MS: relevance to white matter changes and disability”. Neurology. 60 (7): 1157–62. PMID 12682324.
- ↑ Dehmeshki J, Chard DT, Leary SM, Watt HC, Silver NC, Tofts PS, Thompson AJ, Miller DH (2003). “The normal appearing grey matter in primary progressive multiple sclerosis: a magnetisation transfer imaging study”. J. Neurol. 250 (1): 67–74. doi:10.1007/s00415-003-0955-x. PMID 12527995.
- ↑ Martínez-Lapiscina EH, Ayuso T, Lacruz F, Gurtubay IG, Soriano G, Otano M, Bujanda M, Bacaicoa MC (2013). “Cortico-juxtacortical involvement increases risk of epileptic seizures in multiple sclerosis”. Acta Neurol. Scand. 128 (1): 24–31. doi:10.1111/ane.12064. PMID 23289848.
- ↑ Haider L, Simeonidou C, Steinberger G, Hametner S, Grigoriadis N, Deretzi G, Kovacs GG, Kutzelnigg A, Lassmann H, Frischer JM (2014). “Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron”. J. Neurol. Neurosurg. Psychiatry. 85 (12): 1386–95. doi:10.1136/jnnp-2014-307712. PMC 4251183. PMID 24899728.
- ↑ Lucchinetti CF, Popescu BF, Bunyan RF, Moll NM, Roemer SF, Lassmann H, Brück W, Parisi JE, Scheithauer BW, Giannini C, Weigand SD, Mandrekar J, Ransohoff RM (2011). “Inflammatory cortical demyelination in early multiple sclerosis”. N. Engl. J. Med. 365 (23): 2188–97. doi:10.1056/NEJMoa1100648. PMC 3282172. PMID 22150037.
- ↑ 21.0 21.1 Bramow S, Frischer JM, Lassmann H, Koch-Henriksen N, Lucchinetti CF, Sørensen PS, Laursen H (2010). “Demyelination versus remyelination in progressive multiple sclerosis”. Brain. 133 (10): 2983–98. doi:10.1093/brain/awq250. PMID 20855416.
- ↑ Kuhlmann T, Miron V, Cui Q, Cuo Q, Wegner C, Antel J, Brück W (2008). “Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis”. Brain. 131 (Pt 7): 1749–58. doi:10.1093/brain/awn096. PMID 18515322.
- ↑ Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Brück W, Lucchinetti C, Lassmann H (2006). “Remyelination is extensive in a subset of multiple sclerosis patients”. Brain. 129 (Pt 12): 3165–72. doi:10.1093/brain/awl217. PMID 16921173.
- ↑ Bin JM, Rajasekharan S, Kuhlmann T, Hanes I, Marcal N, Han D, Rodrigues SP, Leong SY, Newcombe J, Antel JP, Kennedy TE (2013). “Full-length and fragmented netrin-1 in multiple sclerosis plaques are inhibitors of oligodendrocyte precursor cell migration”. Am. J. Pathol. 183 (3): 673–80. doi:10.1016/j.ajpath.2013.06.004. PMID 23831296.
- ↑ Franklin RJ, Gallo V (2014). “The translational biology of remyelination: past, present, and future”. Glia. 62 (11): 1905–15. doi:10.1002/glia.22622. PMID 24446279.
- ↑ Dessa Sadovnick A (July 2002). “The genetics of multiple sclerosis”. Clin Neurol Neurosurg. 104 (3): 199–202. PMID 12127654.
- ↑ Ramagopalan SV, Dyment DA (March 2011). “What is Next for the Genetics of Multiple Sclerosis?”. Autoimmune Dis. 2011: 519450. doi:10.4061/2011/519450. PMC 3085300. PMID 21541245.
- ↑ Kutzelnigg A, Lassmann H (2014). “Pathology of multiple sclerosis and related inflammatory demyelinating diseases”. Handb Clin Neurol. 122: 15–58. doi:10.1016/B978-0-444-52001-2.00002-9. PMID 24507512.
- ↑ Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, Howell O (2011). “The neuropathological basis of clinical progression in multiple sclerosis”. Acta Neuropathol. 122 (2): 155–70. doi:10.1007/s00401-011-0840-0. PMID 21626034.
- ↑ Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H (2000). “Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination”. Ann. Neurol. 47 (6): 707–17. PMID 10852536.
- ↑ Lassmann H, Brück W, Lucchinetti C (2001). “Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy”. Trends Mol Med. 7 (3): 115–21. PMID 11286782.
- ↑ Ziabreva I, Campbell G, Rist J, Zambonin J, Rorbach J, Wydro MM, Lassmann H, Franklin RJ, Mahad D (2010). “Injury and differentiation following inhibition of mitochondrial respiratory chain complex IV in rat oligodendrocytes”. Glia. 58 (15): 1827–37. doi:10.1002/glia.21052. PMC 3580049. PMID 20665559.
Causes
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
Multiple sclerosis may be caused by different categories of causes include: Autoimmunity, genetic, infectious and degeneration.
Causes
Common Causes
Common causes of multiple sclerosis may include:
- Autoimmunity:
- The primary hypothesis regarding MS etiology states that it is caused by an autoimmune reaction against the central nervous system (CNS).[1]
- Self reactive T cells which has been activated by a foreign (such as virus) or native factor will attack the myelin sheath around the neurons.[2]
- Presence of autoreactive T cells and myelin basic protein-specific CD4+ T cells in the peripheral blood smear of MS patients supports the autoimmune hypothesis.[3][4]
- Infectious:
- Infections including Epstein-Barr virus, chlamydia, and herpes virus seems to have some relations to MS based on finding pathogenic proteins and nucleic acids in post mortem patients.[5][6][7]
- Degeneration:
References
- ↑ Compston A, Coles A (2008). “Multiple sclerosis”. Lancet. 372 (9648): 1502–17. doi:10.1016/S0140-6736(08)61620-7. PMID 18970977.
- ↑ Korn T (2008). “Pathophysiology of multiple sclerosis”. J. Neurol. 255 Suppl 6: 2–6. doi:10.1007/s00415-008-6001-2. PMID 19300953.
- ↑ Pette M, Fujita K, Kitze B, Whitaker JN, Albert E, Kappos L, Wekerle H (1990). “Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals”. Neurology. 40 (11): 1770–6. PMID 1700336.
- ↑ Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, McFarland HF, Martin R (2000). “Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand”. Nat. Med. 6 (10): 1167–75. doi:10.1038/80516. PMID 11017150.
- ↑ Sriram S, Mitchell W, Stratton C (1998). “Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS”. Neurology. 50 (2): 571–2. PMID 9484408.
- ↑ Soldan SS, Jacobson S (2001). “Role of viruses in etiology and pathogenesis of multiple sclerosis”. Adv. Virus Res. 56: 517–55. PMID 11450311.
- ↑ Mechelli R, Manzari C, Policano C, Annese A, Picardi E, Umeton R, Fornasiero A, D’Erchia AM, Buscarinu MC, Agliardi C, Annibali V, Serafini B, Rosicarelli B, Romano S, Angelini DF, Ricigliano VA, Buttari F, Battistini L, Centonze D, Guerini FR, D’Alfonso S, Pesole G, Salvetti M, Ristori G (2015). “Epstein-Barr virus genetic variants are associated with multiple sclerosis”. Neurology. 84 (13): 1362–8. doi:10.1212/WNL.0000000000001420. PMC 4388746. PMID 25740864.
- ↑ Friese MA, Schattling B, Fugger L (2014). “Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis”. Nat Rev Neurol. 10 (4): 225–38. doi:10.1038/nrneurol.2014.37. PMID 24638138.
- ↑ Kutzelnigg A, Lucchinetti CF, Stadelmann C, Brück W, Rauschka H, Bergmann M, Schmidbauer M, Parisi JE, Lassmann H (2005). “Cortical demyelination and diffuse white matter injury in multiple sclerosis”. Brain. 128 (Pt 11): 2705–12. doi:10.1093/brain/awh641. PMID 16230320.
Differentiating Multiple sclerosis from other Diseases

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
Multiple sclerosis must be differentiated from other diseases that can mimic this disease clinically or radiologically such as systemic lupus erythematosis, Sjögren’s syndrome, vasculitis, neuro-behçet’s disease, sarcoidosis, antiphospholipid (Hughes) syndrome , susac syndrome, lyme disease, syphilis, HTLV-1 infection, HIV-Related Disorders of the CNS, migraine, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, leber’s hereditary optic neuropathy, vitamin B12 deficiency, metachromatic leukodystrophy, Fabry’s disease, Krabbe’s disease, adrenoleukodystrophy, mitochondrial encephalopathy epilepsy lactic acidosis and stroke like episode, stroke, primary CNS lymphoma , and dural arteriovenous fistula and true malformations.
Differentiating multiple sclerosis from other diseases
Multiple sclerosis must be differentiated from other diseases that can mimic this disease clinically or radiologically such as:
Inflammatory/autoimmune conditions:
- systemic lupus erythematosus: Systemic lupus erythromatosus can cause neurological manifestations such as seizures, movement disorders, transverse myelitis, cranial and peripheral neuropathies, and optic nerve involvement. In the brain MRI of SLE patients, there are pieces of evidence of atrophy and subcortical white matter lesions. SLE is diagnosed based on systemic manifestations, present of oligoclonal bands and IgG in CSF and high titer of antinuclear antibodies.
- Sjögren’s syndrome: Sjogren disease can cause neurological manifestations including cerebral vasculitis, myopathy, transverse myelitis and acute optic neuropathy. There are evidence of oligoclonal band and increased IgG in CSF and white matter lesions in MRI. Sicca syndrome, rheumatic manifestation and high titers of ANA. SSRo and SS-La will confirm the diagnosis.
- Vasculitis: Wegener’s granulomatosis and polyarteritis nodosa are sometimes categorized as a differential diagnosis of MS, but the most common vasculitis which can mimic MS, is isolated angitis of the central nervous system (IACNS). IACNS is an inflammatory disease with an unknown cause. It affects small and medium sized arteries in the brain parenchyma and meninges. Neurological manifestation of this disease is headache, personality change, paresis, seizures, cranial neuropathy and intracerebral /subarachnoid hemorrhages. There are monoclonal bands and increased protein and lymphocytic pleocytosis and IgG levels in the CSF of this patients. MRI may show patchy or diffuse increased signal in periventricular and subcortical white matter. diagnosis is made by evidences of vasculitis changes in angiography or biopsy.
- Neuro-behçet’s disease: Behcet’s disease is an idiopathic inflammatory disorder and can manifest as a triad of oral and genital ulcers and anterior uveitis. Lungs, gastrointestinal tract, joint, and skin can be involved too. Rarely, neurological signs can be the first manifestation of the disease. The most common neurological manifestation of behcet’s disease is psychiatric symptoms, intranuclear ophthalmoplegia, headache and sensory/motor deficits. The course of the disease can be relapsing remitting or progresive. In the CSF specimen we can see high levels of protein, pleocytosis (granulocytic, unlike MS) and oligoclonal bands (which can be suppressed by corticosteroid treatment). In MRI the most common involvement can be seen in brain stem and basal ganglia.
- sarcoidosis: Sarcoidosis is an inflammatory disease with formation of non caseating epitheloid granulomata. It’s a multisystem disease but affects lungs more than other organs. There is a 5-10% change of neurological involvement and in 50 % of these patients neurological involvement can be the first sign or symptoms. It usually affects cranial nerves, hypothalamus and pituitary gland. involvement of optic nerve, brain stem and spinal cord can mimic MS symptoms. In MRI we can see an isolated or diffuse lesion in brain parenchyma or even periventricular white matter lesion like MS. CSF analysis can be very same to MS but in sarcoidosis we have elevated amount of angiotensin converting enzyme.
- Antiphospholipid (Hughes) syndrome: In antiphospholipid syndrome, the presence of anticardiolipin and/or lupus anticoagulant can cause arterial and venous thrombosis. It can cause neurological manifestations like transient ischemic attack, ischemic encephalopathy, thrombosis of cerebral veins, seizure, headache, guillain barre syndrome, dementia, chorea and optic nerve neuropathy. In MRI there is evidence of white matter T2 hyperintense and/or cortical lesions. The latter is in favor of APS. In CSF analysis lack of oligoclonal bands is against the MS diagnosis. Differentiating MS from APS is so difficult that it’s recommended to treat MS patients for APS too.
- Susac syndrome: Susac syndrome is an idiopathic disease that causes microangiopathy of brain, retina, and cochlea arterioles. Involvement of this arterioles leads to visual disturbance, hearing loss, and encephalopathy. In MRI there is white and gray matter lesions and leptomeningeal involvement. CSF analysis shows elevated protein level and pleocytosis.
Infections:
- Lyme disease: Borrelia burgdorferi is transmitted through a tick bite and can cause rash (erythema chronica migrans) typical for lyme disease. This disease can affect cranial nerves especially seventh nerve. It is usually easily differentiated from MS because of meningitis involvement in MRI and pleocytosis as well as high lyme titer in CSF.
- syphilis: Neurosyphilis, more commonly seen in HIV+ patients can be in two forms. One can be seen in late secondary or early tertiary stages as meningovascular involvement and the other one can be seen in later stages as parenchymal involvement. Meningovascular lesions can present like a stroke while the other one cause gummas (contrast enhancing lesions). In CSF, there are pieces of evidence of oligoclonal bands, pleocytosis, and elevated gammaglobulin.
- Progressive multifocal leukoencephalopathy: Progressive multifocal leukoencephalopathy (PML) is cause by activation of JC virus and is more commonly seen in immunocompromised patients. Some evidences shows the relation between PML and drug natalizumab. In MRI of PML patients we see multiple white matter lesions that can become confluent with no enhancement in T1. Diagnosis of PML is based on detecting JC virus in CSF.
- HTLV-1 infection: Human T lymphotrophic virus, transmitted through sexual activity, can cause tropical spastic paraparesis. The involvement of spinal cord and MRI pattern of Tropical spastic paraparesis can mimic MS disease. In CSF we have positive HTLV-1 titer, lymphocytic pleocytosis, oligoclonal bands and high level of proteins.
- HIV-Related Disorders of the CNS: HIV infection frequently involves CNS and can be the initial manifestation of the disease. In an MRI, there are white matter lesions. In a CSF analysis, there are high levels of proteins and cell counts but oligoclonal bands are rarely seen.
Metabolic and Genetic/Heriditary Disorders:
- Migraine: Migraine is a throbbing headache, which worsens by sound and light. It can cause a variety of transient neurological manifestation including sensory loss, visual loss, ophtalmoparesis, and vertigo. These manifestations can occur before or with the migraine headache but in some cases, which we call “amigrainous migraine”, we have neurological problems without headache. In an MRI of these patients, we can see small areas of deep frontal white matter lesions.
- Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy:
- Leber’s hereditary optic neuropathy: Leber’s hereditary optic neuropathy is caused by mitochondirial DNA mutation. It presents as acute bilateral blindness. The MRI finding of MS and LHON are alike and make it difficult to differentiate them.
- Vitamin B12 deficiency: B12 deficiency can cause neurological manifestation including peripheral neuropathy, optic neuropathy, cervical myelopathy, and fatigue. MRI findings include contrast enhancement of posterior and lateral spinal cord columns preferably in cervical and thoracic levels.
- Lysosomal disorders:
- Metachromatic leukodystrophy: MLD is an autosomal recessive lysosomal storage disease that leads to accumulation of galactosyl sulfatide.
- Fabry’s disease: X-linked disease with impaired activity of a-galactosidase leading to accommodation of globotriaosylceramide in many organs including ganglion cells of the autonomic nervous system.
- Krabbe’s disease: Autosomal recessive disease with impaired activity of galactocerebrosidase leading to destruction of CNS and PNS myelin and axonal degeneration.
- Adrenoleukodystrophy: ALD disease causes accumulation of long chain fatty acids. X-linked type of this disease (adrenomyeloneuropathy) will cause spinal cord disease and peripheral neuropathy and can be considered as a differential diagnosis of MS disease.
- mitochondrial encephalopathy epilepsy lactic acidosis and stroke: One of the mitochondrial diseases that can categorized as a MS differential diagnosis in mitochondrial encephalopathy epilepsy lactic acidosis and stroke (MELAS). The manifestations include: Seizures, exercise intolerance, limb weakness, stroke like episodes, hemiparesis and hemianopia. There are evidences of calcium deposition in caudate nucleus and globus pallidus in CT scan and cortical involvement in MRI imaging.
CNS lymphoma
Primary CNS lymphoma is mostly diffuse large B-cell lymphoma (DLBCL). These patients more commonly present with neurological manifestation rather than B symptoms. In MRI evaluation, because of high cell count and scant cytoplasm lesions become isotense to hypointense on T2. In CSF analysis, there are increased number of WBC and proteins, low levels of glucose and positive cytology for cells with enlarged nucleus and course chromatin.
spinal diseases
Dural arteriovenous fistula and true malformations can be mistaken with MS since they can all cause thoracic myelopathy.
References
Epidemiology and Demographics
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
The majority of multiple sclerosis cases are reported in northern Europe, continental North America, and Australasia, which is about one of every 1000 citizens. Factors including sunlight exposure, climate, diet, toxins, genetic factors, geomagnetism, childhood environmental factors, and infections have been proved to cause the differences in MS prevalence. MS is at least two times more common among women than men. The onset of symptoms is mostly between the age of fifteen to forty years, rarely before age fifteen or after age sixty.
Epidemiology and Demographics
Incidence
- The incidence of multiple sclerosis is approximately 200 new cases per week in united state.
Prevalence
- The prevalence of MS varies among countries. according to some studies MS occurs mostly in Caucasians while it is rare in the Native American tribes of North America, Australian Aborigines and the Māori of New Zealand.
- Among countries Scotland seems to have the highest rate of MS in the world.[1]
- We can conclude that due to genetic susceptibility, lifestyle and different culture, the development of this disease is not equal in various regions.
Case-fatality rate/Mortality rate
Age
- The onset of symptoms is mostly between the age of fifteen to forty years, rarely before age fifteen or after age sixty.
Race
- MS prevalence is lower in African Americans, Mexicans, Japanese, Chinese and Filipinos people rather than white men.[2]
Gender
- Autoimmune disorders such as MS is at least two times more common among women than men but this difference will disappear after the age of 50 and in children reach three females for each male.
Region
- The majority of multiple sclerosis cases are reported in northern Europe, continental North America, and Australasia, which is about one of every 1000 citizens while there is a lower frequency of people suffering from Multiple Sclerosis among citizens of the Arabian Peninsula, Asia, and continental South America. In addition, in sub-Saharan Africa, MS is extremely rare.[3]
- Factors including sunlight exposure, climate, diet, toxins, genetic factors, geomagnetism, Childhood environmental factors and infections have been proved to cause this differences in MS prevalence.
- Several studies demonstrated that if immigration occurs before the age of fifteen, the migrant’s susceptibility to MS will be equal to that region’s native people, But if migration occurs after the age of fifteen, the migrant’s susceptibility will remain equal to his home country.[4]
It is important to say that some studies on related diseases have shown that some diseases which were formerly considered MS cases are not MS at all. all the studies before 2004 can be affected because of inability to distinguish MS and Devic’s disease (NMO).[5]

References
- ↑ Rothwell PM, Charlton D (1998). “High incidence and prevalence of multiple sclerosis in south east Scotland: evidence of a genetic predisposition”. J. Neurol. Neurosurg. Psychiatr. 64 (6): 730–5. PMID 9647300.
- ↑ Kurtzke JF, Beebe GW, Norman JE (September 1979). “Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution”. Neurology. 29 (9 Pt 1): 1228–35. PMID 573402.
- ↑ Epidemiology and multiple sclerosis. a personal review
- ↑ Marrie, RA. Environmental risk factors in multiple sclerosis etiology. Lancet Neurol. 2004 Dec;3(12):709-18. Review. PMID 15556803
- ↑ Weinshenker B (2005). “Western vs optic-spinal MS: two diseases, one treatment?”. Neurology. 64 (4): 594–5. PMID 15728277.
Risk Factors
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.,
Overview
Common risk factors in the development of multiple sclerosis are smoking, genetic, ethnic, infection, low vitamin D, and stress. Less common risk factors in the development of multiple sclerosis include African Americans, Mexicans, Japanese, Chinese and Filipinos race and Epstein-Barr virus.
Risk Factors
Common Risk Factors
- Common risk factors in the development of multiple sclerosis include:
- Smoking: Various studies show that smoking, beside cardiovascular diseases and cancer, can be a risk factor of multiple sclerosis.[1][2]
- Genetic: Studies demonstrate that MS has a strong genetic base. The first degree family of a MS patient is at a 10-25 times greater risk than normal population, so genetically susceptible people are more likely to develop MS disease.[3][4]
- Gender: Prevalence of MS disease is higher in female. This can be hormone related or more susceptibility to environmental risk factors.[5][6]
- Vitamin D: Low vitamin D level seems to be a risk factor for developing MS since the prevalence of MS is lower in regions where people take vitamin D supplement or have higher sunlight exposure.[7][8]
- Stress: Stressful life events can be a risk factor for MS disease. In patients who already have MS, stress and anxiety can lead to exacerbation of their disease.[9][10]
Less Common Risk Factors
- Less common risk factors in the development of multiple sclerosis include:
- Ethnic: MS prevalence is lower in African Americans, Mexicans, Japanese, Chinese and Filipinos people rather than white men.[11]
- Epstein-Barr virus: Patients affected with Epstein-Barr virus seems to be more susceptible to developing MS. Studies shows that high titre of EBV antibodies is a risk factor for MS disease.[12][13]
References
- ↑ Riise T, Nortvedt MW, Ascherio A (October 2003). “Smoking is a risk factor for multiple sclerosis”. Neurology. 61 (8): 1122–4. PMID 14581676.
- ↑ Hernán MA, Olek MJ, Ascherio A (July 2001). “Cigarette smoking and incidence of multiple sclerosis”. Am. J. Epidemiol. 154 (1): 69–74. PMID 11427406.
- ↑ Robertson NP, Fraser M, Deans J, Clayton D, Walker N, Compston DA (April 1996). “Age-adjusted recurrence risks for relatives of patients with multiple sclerosis”. Brain. 119 ( Pt 2): 449–55. PMID 8800940.
- ↑ Sadovnick AD, Baird PA, Ward RH (March 1988). “Multiple sclerosis: updated risks for relatives”. Am. J. Med. Genet. 29 (3): 533–41. doi:10.1002/ajmg.1320290310. PMID 3376997.
- ↑ Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, Ebers GC (November 2006). “Sex ratio of multiple sclerosis in Canada: a longitudinal study”. Lancet Neurol. 5 (11): 932–6. doi:10.1016/S1474-4422(06)70581-6. PMID 17052660.
- ↑ Whitacre CC (September 2001). “Sex differences in autoimmune disease”. Nat. Immunol. 2 (9): 777–80. doi:10.1038/ni0901-777. PMID 11526384.
- ↑ van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R, Taylor BV, Butzkueven H, Kilpatrick T (August 2003). “Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study”. BMJ. 327 (7410): 316. doi:10.1136/bmj.327.7410.316. PMC 169645. PMID 12907484.
- ↑ Munger KL, Zhang SM, O’Reilly E, Hernán MA, Olek MJ, Willett WC, Ascherio A (January 2004). “Vitamin D intake and incidence of multiple sclerosis”. Neurology. 62 (1): 60–5. PMID 14718698.
- ↑ Coo H, Aronson KJ (2004). “A systematic review of several potential non-genetic risk factors for multiple sclerosis”. Neuroepidemiology. 23 (1–2): 1–12. doi:10.1159/000073969. PMID 14739563.
- ↑ Goodin DS, Ebers GC, Johnson KP, Rodriguez M, Sibley WA, Wolinsky JS (June 1999). “The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology”. Neurology. 52 (9): 1737–45. PMID 10371517.
- ↑ Kurtzke JF, Beebe GW, Norman JE (September 1979). “Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution”. Neurology. 29 (9 Pt 1): 1228–35. PMID 573402.
- ↑ Sundström P, Juto P, Wadell G, Hallmans G, Svenningsson A, Nyström L, Dillner J, Forsgren L (June 2004). “An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study”. Neurology. 62 (12): 2277–82. PMID 15210894.
- ↑ Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET, Spiegelman D, Ascherio A (May 2005). “Temporal relationship between elevation of epstein-barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis”. JAMA. 293 (20): 2496–500. doi:10.1001/jama.293.20.2496. PMID 15914750.
Screening
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
There is insufficient evidence to recommend routine screening for multiple sclerosis.
Screening
There is insufficient evidence to recommend routine screening for multiple sclerosis.
References
Natural History, Complications and Prognosis
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
Multiple sclerosis usually start between age of fifteen to forty years, rarely before age fifteen or after age sixty with symptoms such as optic neuritis, diplopia, sensory or motor loss, vertigo and balance problems. It may be classified into four groups according to clinical course of the disease including relapsing-remitting, secondary-progressive, primary-progressive, and progressive-relapsing. Complications that can develop as a result of multiple sclerosis are: medication complication, Fatigue, mood problems, Spasticity, Bowel and bladder dysfunction, Cognitive impairment, Heat sensitivity., Incoordination, Pain, Sexual dysfunction, Sleep disorders, vertigo, visual loss. there are some factors associated with a particularly poor prognosis among patients with multiple sclerosis such as: Relapsing versus progressive disease, early symptoms, Demographics, Sex, Smoking.
Natural History, Complications, and Prognosis
Natural History
- Multiple sclerosis usually start between age of fifteen to forty years, rarely before age fifteen or after age sixty with symptoms such as optic neuritis, diplopia, sensory or motor loss, vertigo, and balance problems. In young adult eye and sensory problems are prominent while in older patients we see motor problems more often.[1]
- The natural history of the disease is either relapsing or progressive.
- Relapsing-remitting multiple sclerosis is defined by acute attacks of neurological dysfunction followed by full or partial recovery. Patient clinical symptoms are stable between the attacks.
- It can switch to secondary progressive disease when the neurological symptoms progressively worsen between the attacks.
- There is also primary progressive type, which is defined by continuously worsening of neurological dysfunction with no distinct attacks and remissions.
- Progressive relapsing type is a mixture of relapsing and progression and is defined by progression of disease from the beginning with acute attack episodes.[2]
- The most common symptoms in all of the MS patients are fatigue, mood problems, spasticity, bowel and bladder dysfunction, cognitive impairment, eye movement abnormalities, heat sensitivity, incoordination , pain, sexual dysfunction, sleep disorders, vertigo, and visual loss.[3][4][5][6][7][8][9][10][11][12][13][14][15]
Complications
Complications that can develop as a result of mutiple sclerosis include:
- Medication complications: Insufficient blood supply to the bone can cause avascular osteonecrosis. After trauma, corticosteroid treatment is the most common cause of AVN.[16][17]
- Fatigue: Fatigue is seen in almost 80% of MS patients. They commonly feel exhausted and out of energy. We can see fatigue exacerbation before acute attacks in MS and for a while after that.[18]
- Mood problems: Psychiatric disorders especially depression is common and can be seen in almost 50% of MS patients.[5] Some studies show higher risk of suicide in MS patient.[19][20]
- Spasticity: Damage to the upper motor neurons and decrease inhibition of lower motor neurons in MS can increase muscle tone and rigidity in 75% of MS patients.[6]
- Bowel and bladder dysfunction: Bowel and bladder dysfunction is common in MS patients and occurs in more than 50% of cases.[7] bladder dysfunction can be the result of Detrusor overactivity, Detrusor sphincter dyssynergia, Inefficient bladder contractility and Abnormal sensation and bladder hypoactivity.[21] the most common bowel problems include Constipation, poor defecation and incontinence.[22]
- Cognitive impairment: Cognitive disorders is common in MS patients and can even present at early stages of disease. These disorders are in attention, short term memory, and information processing. Relapsing-remitting type of MS seems to have a lower cognitive problems.[8][23][24][25]
- Heat sensitivity: Patients with MS disease are more sensitive to heat. A slight increase in body temperature of these patients will lead to worsening of their signs and symptoms.[10]
- Incoordination: Involvement of cerebellar tracts can cause problems in Gait and balance, poor coordinated actions, and slurred speech. Intention tremor is present in most of these patients.[11]
- Pain: Pain is a very common symptom in MS. Patients can be either from neurogenic source leading to burning or ice-cold dysesthesias or from long immobilization and spasm.[12][26]
- Sexual dysfunction: Sexual dysfunction can be due to involvement of motor and sensory pathways or from psychological problems. Either way, it’s a very common symptom. In women, we can see reduced libido and orgasm, dyspareunia and decrease vaginal sensation. Presentations of sexual dysfunction in men are decreased libido and premature ejaculation, erectile dysfunction and decreased penile sensation.[13][27]
- Sleep disorders: Many patients with multiple sclerosis suffer from sleep disorders and daytime somnolence. This can be the result of so many conditions including restless leg syndrome, nocturia, pain, and medication side effects. Having more cervical lesions lead to experiencing restless leg syndrome more often.[14][28][29]
- Vertigo: Benign positional paroxysmal vertigo is the most common cause of vertigo in an MS patient. In the course of the disease about 30-50% of patients experience this symptom.[15]
- Visual loss: Optic neuritis is the most common eye involvement and presents as an acute unilateral eye pain, followed by some degree of vision loss.[3]
Prognosis
There are some factors associated with a particularly poor prognosis among patients with multiple sclerosis. However, we can’t surly say what is the prognosis of MS patients.[30]
- Relapsing versus progressive disease: Progressive form of MS seems to have a worse prognosis in comparison to relapsing remitting form of MS. Disabilities start sooner in progressive form[31][32][33] but some studies showed that age of onset is more important in MS disability than the form of the disease.[34][35]
- Early symptoms: Some first manifestations of MS disease like bowel and bladder dysfunction seem to have a worse prognosis.[36]. Another study demonstrated that having so many symptoms at the onset of the disease have a worse prognosis than being monosymptom.[37]
- Demographics: Onset of MS in Black Americans is in later age and they are more susceptible of having multifocal signs and symptoms and involvement of optic nerve and spinal cord.[38]
- Lipid specific immunoglobulin level: Lipid specific immunoglobulin level in CSF can predict long term outcomes of MS disease.[40]
References
- ↑ Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (February 1989). “The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability”. Brain. 112 ( Pt 1): 133–46. PMID 2917275.
- ↑ Lublin FD, Reingold SC (April 1996). “Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis”. Neurology. 46 (4): 907–11. PMID 8780061.
- ↑ 3.0 3.1 Balcer LJ (March 2006). “Clinical practice. Optic neuritis”. N. Engl. J. Med. 354 (12): 1273–80. doi:10.1056/NEJMcp053247. PMID 16554529.
- ↑ Čarnická Z, Kollár B, Šiarnik P, Krížová L, Klobučníková K, Turčáni P (April 2015). “Sleep disorders in patients with multiple sclerosis”. J Clin Sleep Med. 11 (5): 553–7. doi:10.5664/jcsm.4702. PMC 4410929. PMID 25700869.
- ↑ 5.0 5.1 Sadovnick AD, Remick RA, Allen J, Swartz E, Yee IM, Eisen K, Farquhar R, Hashimoto SA, Hooge J, Kastrukoff LF, Morrison W, Nelson J, Oger J, Paty DW (March 1996). “Depression and multiple sclerosis”. Neurology. 46 (3): 628–32. PMID 8618657.
- ↑ 6.0 6.1 Boissy AR, Cohen JA (September 2007). “Multiple sclerosis symptom management”. Expert Rev Neurother. 7 (9): 1213–22. doi:10.1586/14737175.7.9.1213. PMID 17868019.
- ↑ 7.0 7.1 DasGupta R, Fowler CJ (2003). “Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies”. Drugs. 63 (2): 153–66. PMID 12515563.
- ↑ 8.0 8.1 Achiron A, Barak Y (April 2003). “Cognitive impairment in probable multiple sclerosis”. J. Neurol. Neurosurg. Psychiatry. 74 (4): 443–6. PMC 1738365. PMID 12640060.
- ↑ Frohman EM, Frohman TC, Zee DS, McColl R, Galetta S (February 2005). “The neuro-ophthalmology of multiple sclerosis”. Lancet Neurol. 4 (2): 111–21. doi:10.1016/S1474-4422(05)00992-0. PMID 15664543.
- ↑ 10.0 10.1 Selhorst JB, Saul RF (June 1995). “Uhthoff and his symptom”. J Neuroophthalmol. 15 (2): 63–9. PMID 7550931.
- ↑ 11.0 11.1 Rinker JR, Salter AR, Walker H, Amara A, Meador W, Cutter GR (January 2015). “Prevalence and characteristics of tremor in the NARCOMS multiple sclerosis registry: a cross-sectional survey”. BMJ Open. 5 (1): e006714. doi:10.1136/bmjopen-2014-006714. PMC 4289717. PMID 25573524.
- ↑ 12.0 12.1 Drulovic J, Basic-Kes V, Grgic S, Vojinovic S, Dincic E, Toncev G, Kezic MG, Kisic-Tepavcevic D, Dujmovic I, Mesaros S, Miletic-Drakulic S, Pekmezovic T (August 2015). “The Prevalence of Pain in Adults with Multiple Sclerosis: A Multicenter Cross-Sectional Survey”. Pain Med. 16 (8): 1597–602. doi:10.1111/pme.12731. PMID 26087108.
- ↑ 13.0 13.1 Lew-Starowicz M, Gianotten WL (2015). “Sexual dysfunction in patients with multiple sclerosis”. Handb Clin Neurol. 130: 357–70. doi:10.1016/B978-0-444-63247-0.00020-1. PMID 26003254.
- ↑ 14.0 14.1 Manconi M, Rocca MA, Ferini-Strambi L, Tortorella P, Agosta F, Comi G, Filippi M (January 2008). “Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage”. Mult. Scler. 14 (1): 86–93. doi:10.1177/1352458507080734. PMID 17942519.
- ↑ 15.0 15.1 Frohman EM, Zhang H, Dewey RB, Hawker KS, Racke MK, Frohman TC (November 2000). “Vertigo in MS: utility of positional and particle repositioning maneuvers”. Neurology. 55 (10): 1566–9. PMID 11094117.
- ↑ Yamamoto T, Irisa T, Sugioka Y, Sueishi K (November 1997). “Effects of pulse methylprednisolone on bone and marrow tissues: corticosteroid-induced osteonecrosis in rabbits”. Arthritis Rheum. 40 (11): 2055–64. doi:10.1002/1529-0131(199711)40:11<2055::AID-ART19>3.0.CO;2-E. PMID 9365096.
- ↑ Assouline-Dayan Y, Chang C, Greenspan A, Shoenfeld Y, Gershwin ME (October 2002). “Pathogenesis and natural history of osteonecrosis”. Semin. Arthritis Rheum. 32 (2): 94–124. PMID 12430099.
- ↑ Krupp L (August 2006). “Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease”. Mult. Scler. 12 (4): 367–8. doi:10.1191/135248506ms1373ed. PMID 16900749.
- ↑ Sadovnick AD, Eisen K, Ebers GC, Paty DW (August 1991). “Cause of death in patients attending multiple sclerosis clinics”. Neurology. 41 (8): 1193–6. PMID 1866003.
- ↑ Stenager EN, Stenager E (December 1992). “Suicide and patients with neurologic diseases. Methodologic problems”. Arch. Neurol. 49 (12): 1296–303. PMID 1449409.
- ↑ Wintner A, Kim MM, Bechis SK, Kreydin EI (April 2016). “Voiding Dysfunction in Multiple Sclerosis”. Semin Neurol. 36 (2): 219–20. doi:10.1055/s-0036-1582255. PMID 27116728.
- ↑ Hennessey A, Robertson NP, Swingler R, Compston DA (November 1999). “Urinary, faecal and sexual dysfunction in patients with multiple sclerosis”. J. Neurol. 246 (11): 1027–32. PMID 10631634.
- ↑ Deloire MS, Salort E, Bonnet M, Arimone Y, Boudineau M, Amieva H, Barroso B, Ouallet JC, Pachai C, Galliaud E, Petry KG, Dousset V, Fabrigoule C, Brochet B (April 2005). “Cognitive impairment as marker of diffuse brain abnormalities in early relapsing remitting multiple sclerosis”. J. Neurol. Neurosurg. Psychiatry. 76 (4): 519–26. doi:10.1136/jnnp.2004.045872. PMC 1739602. PMID 15774439.
- ↑ Rao SM, Leo GJ, Bernardin L, Unverzagt F (May 1991). “Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction”. Neurology. 41 (5): 685–91. PMID 2027484.
- ↑ Huijbregts SC, Kalkers NF, de Sonneville LM, de Groot V, Reuling IE, Polman CH (July 2004). “Differences in cognitive impairment of relapsing remitting, secondary, and primary progressive MS”. Neurology. 63 (2): 335–9. PMID 15277630.
- ↑ Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, MacLeod MR, Fallon MT (May 2013). “Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis”. Pain. 154 (5): 632–42. doi:10.1016/j.pain.2012.12.002. PMID 23318126.
- ↑ Zivadinov R, Zorzon M, Bosco A, Bragadin LM, Moretti R, Bonfigli L, Iona LG, Cazzato G (December 1999). “Sexual dysfunction in multiple sclerosis: II. Correlation analysis”. Mult. Scler. 5 (6): 428–31. doi:10.1177/135245859900500i610. PMID 10618700.
- ↑ Amarenco G, Kerdraon J, Denys P (December 1995). “[Bladder and sphincter disorders in multiple sclerosis. Clinical, urodynamic and neurophysiological study of 225 cases]”. Rev. Neurol. (Paris) (in French). 151 (12): 722–30. PMID 8787103.
- ↑ Schürks M, Bussfeld P (April 2013). “Multiple sclerosis and restless legs syndrome: a systematic review and meta-analysis”. Eur. J. Neurol. 20 (4): 605–15. doi:10.1111/j.1468-1331.2012.03873.x. PMID 23078359.
- ↑ Swanton J, Fernando K, Miller D (2014). “Early prognosis of multiple sclerosis”. Handb Clin Neurol. 122: 371–91. doi:10.1016/B978-0-444-52001-2.00015-7. PMID 24507526.
- ↑ 31.0 31.1 Weinshenker BG (1994). “Natural history of multiple sclerosis”. Ann. Neurol. 36 Suppl: S6–11. PMID 8017890.
- ↑ Confavreux C, Vukusic S, Moreau T, Adeleine P (November 2000). “Relapses and progression of disability in multiple sclerosis”. N. Engl. J. Med. 343 (20): 1430–8. doi:10.1056/NEJM200011163432001. PMID 11078767.
- ↑ Tremlett H, Paty D, Devonshire V (January 2006). “Disability progression in multiple sclerosis is slower than previously reported”. Neurology. 66 (2): 172–7. doi:10.1212/01.wnl.0000194259.90286.fe. PMID 16434648.
- ↑ Confavreux C, Vukusic S (March 2006). “Age at disability milestones in multiple sclerosis”. Brain. 129 (Pt 3): 595–605. doi:10.1093/brain/awh714. PMID 16415309.
- ↑ Confavreux C, Vukusic S (March 2006). “Natural history of multiple sclerosis: a unifying concept”. Brain. 129 (Pt 3): 606–16. doi:10.1093/brain/awl007. PMID 16415308.
- ↑ Langer-Gould A, Popat RA, Huang SM, Cobb K, Fontoura P, Gould MK, Nelson LM (December 2006). “Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review”. Arch. Neurol. 63 (12): 1686–91. doi:10.1001/archneur.63.12.1686. PMID 17172607.
- ↑ Kremenchutzky M, Rice GP, Baskerville J, Wingerchuk DM, Ebers GC (March 2006). “The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease”. Brain. 129 (Pt 3): 584–94. doi:10.1093/brain/awh721. PMID 16401620.
- ↑ Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, Glidden D, Weinstock-Guttman B, Reich D, Patterson N, Haines JL, Pericak-Vance M, DeLoa C, Oksenberg JR, Hauser SL (December 2004). “Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis”. Neurology. 63 (11): 2039–45. PMID 15596747.
- ↑ Roudbari SA, Ansar MM, Yousefzad A (July 2013). “Smoking as a risk factor for development of Secondary Progressive Multiple Sclerosis: A study in IRAN, Guilan”. J. Neurol. Sci. 330 (1–2): 52–5. doi:10.1016/j.jns.2013.04.003. PMID 23628463.
- ↑ Thangarajh M, Gomez-Rial J, Hedström AK, Hillert J, Alvarez-Cermeño JC, Masterman T, Villar LM (November 2008). “Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis”. Mult. Scler. 14 (9): 1208–13. doi:10.1177/1352458508095729. PMID 18755821.
Diagnosis
Diagnosis
Diagnostic study of choice | History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X-Ray Findings | Echocardiography and Ultrasound | CT-Scan Findings | MRI Findings | Other Imaging Findings | Other Diagnostic Studies
Treatment
Treatment
Medical Therapy | Surgery | Alternative Therapies | Primary Prevention | Secondary Prevention | Tertiary Prevention | Cost-effectiveness of Therapy | Future or Investigational Therapies
Related Chapters
Related Chapters
Template:Diseases of the nervous system
ar:تصلب الأنسجة المتعدد
bg:Множествена склероза
ca:Esclerosi múltiple
cs:Roztroušená skleróza
de:Multiple Sklerose
el:Πολλαπλή σκλήρυνση
eo:Sklerozo multiloka
fa:اسکلروز چندگانه
id:Sklerosis ganda
it:Sclerosi multipla
he:טרשת נפוצה
hu:Sclerosis multiplex
nl:Multiple sclerose
no:Multippel sklerose
sq:Multiple skleroza
sr:Multipla skleroza
fi:MS-tauti
sv:Multipel skleros
Looking for the patient version?
© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH
